Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 4/20 | 0.52 |
| ▸ | CA2 | P00918 | 5/20 | 0.48 |
| ▸ | CA1 | P00915 | 4/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.47 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.42 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.42 |
| ▸ | ADH1B | P00325 | 1/20 | 0.41 |
| ▸ | ADH1C | P00326 | 1/20 | 0.41 |
| ▸ | ADH1A | P07327 | 1/20 | 0.41 |
| ▸ | ADH4 | P08319 | 1/20 | 0.41 |
| ▸ | ADH7 | P40394 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11692620 | 0.93 | CA1 (0.56) | PPARACA2CA1CA12CA7 | |
| SCHEMBL8951789 | 0.84 | — | — | |
| SCHEMBL2384816 | 0.84 | CA1 (0.35) | PPARACA2CA1CA12CA7 | |
| SCHEMBL29048051 | 0.78 | PPARA (0.57) | PPARACA2CA1CA12CA7 | |
| SCHEMBL4095283 | 0.78 | TGM2 (0.33) | — | |
| SCHEMBL859920 | 0.77 | PPARA (0.50) | PPARACA2CA1CA12CA7 | |
| SCHEMBL28056106 | 0.77 | GRIA1 (0.30) | — | |
| SCHEMBL720606 | 0.75 | PPARA (0.48) | PPARACA2CA1CA12CA7 | |
| SCHEMBL2433753 | 0.75 | MAPK1 (0.46) | ALDH1A1TSHR | |
| SCHEMBL7876619 | 0.75 | PPARA (0.58) | PPARACA2CA1CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0882719-B1 | ARYLETHENESULFONAMIDE DERIVATIVES AND DRUG COMPOSITION CONTAINING THE SAME | YAMANOUCHI PHARMA CO LTD (JP) | 2001-05-16 | — | — | EP | claimed |
| US-6083955-A | HAVING A HIGH AFFINITY FOR DRUGS, ESPECIALLY ENDOSERINE RECEPTORS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2000-07-04 | — | — | US | claimed |
| EP-0882719-A1 | ARYLETHENESULFONAMIDE DERIVATIVES AND DRUG COMPOSITION CONTAINING THE SAME | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1998-12-09 | — | — | EP | claimed |
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20160016956-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-21 | — | — | US | disclosed |
| EP-2433940-B9 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2015-10-28 | — | — | EP | disclosed |
| US-9169254-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-27 | — | — | US | disclosed |
| EP-2433940-B1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2014-09-24 | — | — | EP | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| EP-2433940-A1 | SPIROIMIDAZOLONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-03-28 | — | — | EP | disclosed |
| US-7232904-B2 | Crystal of arylethenesulfonamide derivative and preparation process thereof | ASTELLAS PHARMA INC. (JP) | 2007-06-19 | — | — | US | disclosed |
| US-6083955-A | HAVING A HIGH AFFINITY FOR DRUGS, ESPECIALLY ENDOSERINE RECEPTORS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2000-07-04 | — | — | US | disclosed |
| US-6083955-A | HAVING A HIGH AFFINITY FOR DRUGS, ESPECIALLY ENDOSERINE RECEPTORS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2000-07-04 | — | — | US | disclosed |
| EP-0882719-A4 | ARYLETHENESULFONAMIDE DERIVATIVES AND DRUG COMPOSITION CONTAINING THE SAME | YAMANOUCHI PHARMA CO LTD (JP) | 1999-04-28 | — | — | EP | disclosed |
| CN-1204326-A | Arylvinylsulfonamide derivatives and pharmaceutical compositions thereof | YAMANOUCHI PHARMA CO LTD (JP) | 1999-01-06 | — | — | CN | disclosed |
| CN-1204326-A | Arylvinylsulfonamide derivatives and pharmaceutical compositions thereof | YAMANOUCHI PHARMA CO LTD (JP) | 1999-01-06 | — | — | CN | disclosed |
| EP-0882719-A1 | ARYLETHENESULFONAMIDE DERIVATIVES AND DRUG COMPOSITION CONTAINING THE SAME | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
| EP-0882719-A1 | ARYLETHENESULFONAMIDE DERIVATIVES AND DRUG COMPOSITION CONTAINING THE SAME | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
| WO-1997022595-A1 | ARYLETHENESULFONAMIDE DERIVATIVES AND DRUG COMPOSITION CONTAINING THE SAME | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1997-06-26 | — | — | WO | disclosed |
| US-3944502-A | Process for preparing microcapsules containing hydrophobic oil drops | FUJI PHOTO FILM CO., LTD. (JA) | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | PPARA 1848/4885CA2 921/4885CA1 3253/4885 |
| US-20160016956-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | PPARA 1848/4885CA2 921/4885CA1 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.